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J 2011;45:267–72.Letters to the Editor
P2Y12-Based Platelet Function
Assays Should be Complemented
With Cyclooxygenase-Dependent
Testing in Framing the
Therapeutic Windows for Dual
Antiplatelet Therapy
We read with interest the paper by Cuisset et al. (1) on the subject of
very low on-treatment platelet reactivity (VLTPR) as a measure of
hyper-response to thienopyridines. The efﬁcacy of platelet inhibition
as evaluated by vasodilator-stimulated phosphoprotein (VASP)
phosphorylation ﬂow cytometry assay was used as a predictor of non–
access site–related bleeding events. The absence of information
regarding the periprocedural use of aspirin and the related cyclo-
oxygenase-dependent platelet inhibitory response is a major drawback
of the present study (1). Dual antiplatelet therapy, capitalizing on
different pathways of platelet inhibition, has been paramount inimproving outcomes in patients with acute coronary syndromes within
both the low- and high-risk strata (2). It is unclear from the study by
Cuisset et al. (1) whether their utilization of different thienopyridine
protocols had any impact on aspirin administration or dosing. We
believe that this omission compromises the robustness of the presented
data. By disregarding the variability in the individual responsiveness to
aspirin, the authors have assumed that all patients had a similar level of
platelet inhibition before exposure to thienopyridines. By adhering to
this assumption, the authors have negated the independent contribu-
tion of aspirin response as a confounding variable in their clinical
outcomes trial. The acknowledged widespread variability in aspirin-
induced platelet inhibition may have inﬂuenced both the incidence of
ischemic and bleeding events (3,4). The cumulative effect of dual an-
tiplatelet therapy is achieved by compounding 2 different mechanisms
of anti-aggregation. It stands to reason, therefore, that strategies
designed to delineate the therapeutic window of antiplatelet therapy
need to be more comprehensive than the one presented in the current
study, which focused solely on P2Y12 platelet receptor activity. They
would need to incorporate platelet function testing exploring all drug-
speciﬁc pathways of platelet inhibition implemented in an individual
patient. This point is underscored by the very low sensitivity of the
VLTRP dichotomization threshold of the platelet reactivity index
VASP.The proposedmarker performs sufﬁciently in isolating patients
who are unlikely to suffer a bleeding event. Conversely, its sensitivity
of 17% is clearly inadequate in identifying patients who are prone to
bleeding. The authors demonstrated that patients with VLTRP did
not have a lower thrombotic adverse event rate compared with those
remaining within the targeted therapeutic window. This information
coupled with the high negative predictive value of the platelet reac-
tivity index VASP threshold is interesting and warrants further -
validation. Another issue worth looking into stems from the authors’
decision to exclude patients with a known bleeding diathesis (1).
Although the rationale for selecting a homogenous patient popula-
tion is clear, in doing so the authors have excluded high-risk patients
who are likely to gain the greatest beneﬁt from individualized anti-
platelet therapy management. The aforementioned caveats not-
withstanding, the authors are to be congratulated on highlighting the
importance of documenting interpatient variability in response to
antiplatelet therapy, which is the foundation of subsequent individual
tailoring of platelet inhibition.
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Reply
Reply: P2Y12-Based Platelet Function
Assays Should be Complemented
With Cyclooxygenase-Dependent
Testing in Framing the
Therapeutic Windows for Dual
Antiplatelet Therapy
We thank Drs. Gasparovic and Petricevic for their interest in our
study (1) and their comments. They strongly suggest that P2Y12-
based platelet function assays should be complemented with cyclo-
oxygenase-dependent testing in framing the therapeutic windows for
dual antiplatelet therapy. We think that this statement is highly
speculative and not supported by the available evidence. Indeed,
aspirin resistance has been extensively discussed as a real entity by
itself and its association with clinical outcomes. First, response to
aspirin assessed by cyclooxygenase-dependent testing has probably
been overestimated due to a problem of compliance, and a previous
study by our group showed that noncompliance was the main
explanation for aspirin resistance, being a rare entity in compliant
patients (2). For ischemic risk, some studies suggest the potential
impact of aspirin resistance on ischemic events (3), but a recent study
assessing the beneﬁt of tailored therapy based on platelet testing of
aspirin response failed to show any signiﬁcant beneﬁt (4). Therefore,
testing aspirin response for ischemic prognosis and increasing aspirin
dose on the basis of the test results is not supported by available ev-
idence. For bleeding risk, as assessed in our study, to our knowledge,
no study has ever linked the variability of aspirin response and
bleeding complications in patients undergoing percutaneous coro-
nary intervention after acute coronary syndrome. Therefore, the
proposal in their letter is not in line with current data available on
platelet monitoring. Also, themajor risk of assessing aspirin response
could be to use a higher dose in some patients, whereas recent evi-
dence clearly showed that a high dose of aspirin does not provide any
ischemic beneﬁt, only a constant increase in bleeding and gastroin-
testinal events (5).
Accordingly, we performed an additional analysis to conﬁrm
previous assumptions. In the present study, aspirin response was
assessed by arachidonic acid–induced platelet aggregation (AA-Ag).
The rate of aspirin resistance was very low, with only 60 patients
(4%) with aspirin resistance deﬁned as AA-Ag above the 30%
threshold previously proposed. We did not observe any relationship
between AA-Ag and the occurrence of bleeding complications in
our population, as suggested by Gasparovic et al. This could also be
explained by the biological proﬁle of aspirin response in 1,082
patients (70%) of patients with AA-Ag ¼ 0%. Indeed, to identify apredictor of bleeding with platelet monitoring, we need to deﬁne
hyperresponse, which is probably impossible with a drug providing 0%
in more than two thirds of the patients with the present test.
We appreciate the suggestions of Drs. Gasparovic and Petricevic;
however, this statement is supported neither by available evidence nor
by the new analysis provided in this letter. Therefore, it was not an
omission, and we believe that does not compromise the robustness of
the presented data. Following the proposal to integrate the aspirin
effect into bleeding risk assessment, the next step might be to use the
new P2Y12 blockers as long-term monotherapy without aspirin as
currently tested in the GLOBAL LEADERS study
(NCT01813435).
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Looking for the Native Annulus
After Transcatheter Aortic Valve
Replacement?
I readwith great interest the recently publishedpaperbyBinder et al. (1)
that described the impact of post-implantation SAPIENXT (Edwards
Lifesciences Inc., Irvine, California) geometry and positioning on
clinical outcome after transcatheter aortic valve replacement (TAVR).
